Clinical Trial

Residual Inflammation and Plaque Progression Long-term Evaluation

Study acronym: RIPPLE
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 19, 2024 (before its estimated December 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
Inflammation drives atherosclerotic plaque rupture triggering most acute coronary syndromes. Despite advances in diagnosis and management of atherosclerosis, patients with myocardial infarction (MI) remain at increased risk of recurrent events. The RIPPLE study aims to examine the relationship between residual coronary inflammation detected by 68Ga-DOTATATE PET in patients treated for MI to long-term plaque progression measured by CT coronary angiography (CTCA). The association between infarct-related myocardial 68Ga-DOTATATE PET and myocardial function and viability will also be assessed.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT04073810
Lead Sponsor University of Cambridge
Collaborators: Cambridge University Hospitals NHS Foundation Trust, Wellcome Trust
Conditions Atherosclerosis, Myocardial Infarction, Coronary Artery Disease, Inflammation
Enrollment 40 participants
Start Date 2020-10-01
Primary Completion 2024-12-01 (estimated)
Study Completion 2025-04-01 (estimated)
Updated on ClinicalTrials.gov 2024-07-19